Profile data is unavailable for this security.
About the company
Sosei Group Corporation is a holding company primarily engaged in the biopharmaceutical business. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.
- Revenue in JPY (TTM)12.77bn
- Net income in JPY-7.19bn
- Incorporated1990
- Employees202.00
- LocationSosei Group Corp11F, PMO Hanzomon, 2-1, Koji-machiCHIYODA-KU 102-0083JapanJPN
- Phone+81 352103290
- Fax+81 352103291
- Websitehttps://soseiheptares.com/
More ▼
Mergers & acquisitions
Acquired company | 4565:TYO since announced | Transaction value |
---|---|---|
Idorsia Pharmaceuticals Korea Co Ltd | 9.31% | 135.00k |
Idorsia Pharmaceuticals Japan Ltd | 9.31% | 51.72m |
Idorsia Ltd-Ex-China APAC/Japan Pharmaceuticals business | 9.31% | 465.98m |
Data delayed at least 20 minutes, as of Mar 28 2024 06:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ispace Inc | 1.99bn | -2.52bn | 72.18bn | 216.00 | -- | 19.55 | -- | 36.24 | -33.88 | -33.88 | 24.76 | 44.55 | 0.1476 | -- | 24.87 | 9,219,852.00 | -18.66 | -- | -32.11 | -- | 46.91 | -- | -126.42 | -- | 1.72 | -16.86 | 0.7317 | -- | 46.74 | -- | -180.75 | -- | -- | -- |
Eiken Chemical Co Ltd | 39.90bn | 2.95bn | 80.60bn | 754.00 | 25.54 | 1.49 | 15.39 | 2.02 | 78.83 | 78.83 | 1,067.99 | 1,355.09 | 0.6013 | 2.74 | 3.07 | 52,923,080.00 | 4.44 | 8.83 | 5.45 | 11.34 | 42.67 | 46.39 | 7.38 | 12.16 | 2.95 | -- | 0.0563 | 31.24 | 0.6396 | 4.34 | -7.75 | 17.07 | 0.6216 | 15.33 |
JCR Pharmaceuticals Co Ltd | 41.37bn | 5.36bn | 113.09bn | 879.00 | 20.38 | 1.96 | 13.81 | 2.73 | 42.78 | 42.78 | 330.47 | 445.94 | 0.4253 | 0.5492 | 3.03 | 47,059,160.00 | 5.53 | 9.63 | 8.38 | 14.67 | 74.83 | 74.34 | 12.99 | 19.32 | 1.15 | 19.24 | 0.294 | 27.35 | -32.77 | 10.77 | -74.00 | 4.20 | 53.67 | 25.21 |
Zeria Pharmaceutical Co Ltd | 74.57bn | 8.64bn | 115.75bn | 1.73k | 11.12 | 1.22 | 7.44 | 1.55 | 195.97 | 195.97 | 1,691.65 | 1,780.16 | 0.514 | 1.44 | 3.37 | 43,130,530.00 | 5.96 | 3.37 | 9.31 | 5.40 | 73.90 | 71.45 | 11.60 | 6.52 | 0.8269 | -- | 0.3915 | 41.33 | 14.87 | 1.15 | 56.41 | 8.30 | 5.40 | 3.30 |
Takara Bio Inc | 47.67bn | 1.57bn | 118.61bn | 1.79k | 75.50 | 1.06 | 18.09 | 2.49 | 13.05 | 13.05 | 395.88 | 932.12 | 0.3795 | 1.47 | 2.58 | 26,586,730.00 | 1.27 | 11.78 | 1.38 | 13.36 | 55.32 | 63.90 | 3.34 | 20.22 | 5.81 | -- | 0.00 | 24.13 | 15.43 | 19.32 | -19.33 | 46.97 | 29.87 | 56.32 |
Torii Pharmaceutical Co Ltd | 54.64bn | 4.12bn | 119.09bn | 563.00 | 28.21 | 0.9674 | 26.01 | 2.18 | 146.56 | 146.56 | 1,944.22 | 4,274.44 | 0.4091 | 3.03 | 2.13 | -- | 3.08 | 6.52 | 3.41 | 7.35 | 45.37 | 49.55 | 7.54 | 17.98 | 6.19 | -- | 0.002 | 24.18 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
Kyorin Pharmaceutical Co Ltd | 119.83bn | 4.26bn | 119.98bn | 2.14k | 25.02 | 0.8428 | 14.17 | 1.00 | 74.23 | 74.23 | 2,089.34 | 2,203.28 | 0.678 | 1.34 | 2.73 | 56,047,710.00 | 2.41 | 3.20 | 3.12 | 3.93 | 42.92 | 48.72 | 3.56 | 5.10 | 1.40 | -- | 0.141 | 70.57 | 7.33 | 0.471 | 20.12 | -6.40 | 19.42 | -2.16 |
Mochida Pharmaceutical Co Ltd | 100.09bn | 3.01bn | 123.28bn | 1.53k | 39.01 | 0.919 | 21.38 | 1.23 | 84.34 | 84.34 | 2,768.28 | 3,579.89 | 0.6294 | 1.86 | 2.91 | 65,457,820.00 | 1.89 | 4.86 | 2.26 | 5.94 | 51.24 | 52.20 | 3.01 | 7.36 | 3.24 | -- | 0.00 | 41.96 | -6.28 | -0.6644 | -37.09 | -5.92 | 14.62 | -1.21 |
Sosei Group Corp | 12.77bn | -7.19bn | 143.29bn | 202.00 | -- | 2.14 | -- | 11.22 | -87.73 | -87.73 | 154.90 | 746.93 | 0.0995 | -- | 3.39 | -- | -5.61 | -0.6588 | -6.11 | -0.7036 | 75.70 | 89.83 | -56.34 | -4.46 | 3.62 | -8.25 | 0.5254 | -- | -18.00 | -- | -1,982.98 | -- | -- | -- |
GNI Group Ltd | 26.01bn | 8.09bn | 148.87bn | 701.00 | 18.65 | 4.40 | 14.72 | 5.72 | 160.06 | 160.06 | 531.67 | 678.01 | 0.5402 | 1.78 | 7.33 | -- | 19.74 | 7.23 | 22.65 | 8.78 | 86.24 | 85.75 | 36.54 | 14.57 | 3.67 | 26.42 | 0.0931 | 0.00 | 49.32 | 38.97 | 1,981.71 | -- | 19.69 | -- |
Towa Pharmaceutical Co Ltd | 236.78bn | 11.74bn | 154.34bn | 4.30k | 12.57 | 0.9909 | 4.83 | 0.6518 | 238.42 | 238.42 | 4,810.52 | 3,023.62 | 0.6134 | 1.62 | 3.73 | 55,090,510.00 | 3.04 | 4.73 | 3.80 | 6.39 | 34.66 | 41.27 | 4.96 | 8.06 | 1.48 | -- | 0.5686 | 19.97 | 26.11 | 17.46 | -86.17 | -19.46 | 14.66 | 13.63 |
Sumitomo Pharma Co Ltd | 330.31bn | -173.72bn | 160.35bn | 6.25k | -- | 0.466 | -- | 0.4855 | -437.26 | -437.26 | 831.40 | 864.73 | 0.2717 | 1.36 | 2.71 | 52,849,120.00 | -14.95 | 1.15 | -22.20 | 1.67 | 59.93 | 72.18 | -55.04 | 2.54 | 0.3785 | -- | 0.5452 | 41.44 | -0.8019 | 3.54 | -232.08 | -- | 0.6204 | 3.13 |
KAKEN PHARMACEUTICAL CO., LTD. | 72.10bn | 2.97bn | 164.74bn | 1.13k | 45.89 | 0.9691 | 28.82 | 2.29 | 78.14 | 78.14 | 1,915.49 | 3,700.49 | 0.429 | 1.86 | 2.89 | 63,801,770.00 | 1.76 | 8.17 | 2.00 | 9.56 | 53.89 | 55.55 | 4.11 | 16.09 | 4.68 | -- | 0.0267 | 44.04 | -4.01 | -5.81 | -43.03 | -22.17 | 3.16 | 0.00 |
Kissei Pharmaceutical Co Ltd | 73.72bn | 12.20bn | 175.55bn | 1.80k | 13.36 | 0.8051 | 10.61 | 2.38 | 266.51 | 266.51 | 1,612.29 | 4,421.72 | 0.3213 | 1.68 | 2.60 | 41,067,970.00 | 5.38 | 3.21 | 5.87 | 3.47 | 48.23 | 52.39 | 16.74 | 11.10 | 4.51 | -- | 0.007 | 36.56 | 3.23 | -1.83 | -18.52 | 3.08 | 3.74 | 10.76 |
Peptidream Inc | 28.71bn | 3.04bn | 182.79bn | 569.00 | 60.01 | 4.52 | 33.42 | 6.37 | 23.43 | 23.43 | 221.37 | 311.32 | 0.4307 | 4.52 | 2.66 | -- | 4.55 | -- | 5.34 | -- | 59.97 | -- | 10.57 | -- | 2.88 | 2.80 | 0.3551 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
Data as of Mar 28 2024. Currency figures normalised to Sosei Group Corp's reporting currency: Japanese Yen JPY
Holder | Shares | % Held |
---|---|---|
Taiyo Pacific Partners LPas of 11 Jan 2024 | 6.37m | 7.12% |
Nomura Asset Management Co., Ltd.as of 29 Dec 2023 | 3.07m | 3.43% |
The Vanguard Group, Inc.as of 07 Mar 2024 | 2.58m | 2.89% |
Capital Research & Management Co. (World Investors)as of 15 Feb 2024 | 1.84m | 2.06% |
Asset Management One Co., Ltd.as of 15 Dec 2023 | 1.72m | 1.92% |
Mitsubishi UFJ Asset Management Co., Ltd.as of 08 Mar 2024 | 1.51m | 1.69% |
Capital International KKas of 15 Feb 2024 | 1.35m | 1.51% |
JPMorgan Asset Management (Japan) Ltd.as of 15 Jun 2023 | 1.30m | 1.46% |
Ichiyoshi Asset Management Co., Ltd.as of 19 Dec 2022 | 1.18m | 1.32% |
BlackRock Fund Advisorsas of 07 Mar 2024 | 981.40k | 1.10% |
More ▼
Data from 19 Dec 2022 - 22 Feb 2024Source: FactSet Research Systems Inc.